VCEL vs IMTX Stock Comparison

Vericel and Immatics Prices as of Oct 26, 2026 Peers: Industry group
VCEL Vericel Corp
$43.04 +8.4% 1M +18.5% 1Y
Market cap
$2.22B
P/E
91.8x
Revenue (TTM)
$306.30M
Div. yield
–
Gene and Cell Therapy Healthcare
7 wins
IMTX Immatics N.V.
$7.15 -14.6% 1M -29.8% 1Y
Market cap
$899.26M
P/E
–
Revenue (TTM)
$48.61M
Div. yield
–
Gene and Cell Therapy Healthcare

Head to Head

7 decided of 12

Vericel leads on 7 of the 12 questions below (Vericel 7). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionVCELIMTXLeader
Larger companyMarket capitalisation $2.22B $899.26M VCEL
Cheaper on earningsLower P/E, profitable companies only 91.8x -3.7x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 84.4x — –
Faster revenue growthRevenue growth, trailing twelve months +23.0% -65.4% VCEL
More profitableNet margin, trailing twelve months 7.9% -495.7% VCEL
Better return on capitalReturn on invested capital — — –
Less leveragedLower net debt / EBITDA — — –
Higher dividend yieldTrailing dividend yield 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +18.5% -29.8% VCEL
Better 5-year returnAnnualised price return, 5 years -3.2%/yr -11.9%/yr VCEL
Less volatileAnnualised volatility, 1 year 40.9% 57.7% VCEL
Higher overall scoreMean of the five percentile scores vs peers 81/100 36/100 VCEL

Percentile Scorecard

VCELIMTX

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisVCELIMTX
Valuation 81 #119 of 626 28 #449 of 626
Growth 94 #37 of 604 4 #581 of 604
Profitability 88 #68 of 555 45 #307 of 555
Financial Health 69 #207 of 658 74 #169 of 658
Shareholder Returns 73 #100 of 368 26 #271 of 368
Overall 81 36
  • VCEL ranked among 673 companies in Pharmaceuticals and Biotechnology
  • IMTX ranked among 673 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodVCELIMTXSPY
1 month +8.4%-14.6% -0.8%
3 months -5.0%-17.1% +3.5%
6 months +16.6%-37.0% +7.0%
Year to date +19.5%-31.9% +12.2%
1 year +18.5%-29.8% +13.0%
3 years +31.1%-5.3% +86.3%
3 years, per year +9.5%-1.8% +23.1%
5 years -14.9%-46.8% +68.6%
5 years, per year -3.2%-11.9% +11.0%
10 years +1,693.3%— +258.0%
10 years, per year +33.5%— +13.6%

Risk

MeasureVCELIMTXSPY
Volatility, 1Y 40.9%57.7% 12.7%
Downside volatility, 1Y 40.1%59.2% 12.7%
Beta vs S&P 500, 1Y 0.741.35 1.00
Return / volatility, 1Y 0.45-0.52 1.02
Max drawdown, 5Y -65.4%-75.7% -25.4%
From 52-week high -10.9%-39.8% -1.8%
52-week high $48.31$11.87 $779.14
52-week low $29.34$6.73 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleVCELIMTX
P/E now vs peer median 90.8xmedian 17.1x -3.6xmedian 17.1x
P/S now vs peer median 7.2xmedian 8.8x 19.7xmedian 8.8x
EV/EBITDA now vs peer median 65.0xmedian 17.1x -2.0xmedian 17.1x
P/FCF now vs peer median 35.7xmedian 18.0x -3.9xmedian 18.0x
P/B now vs peer median 6.0xmedian 2.1x 2.1xmedian 2.1x
PEG now vs peer median 1.67median 0.31 0.15median 0.31

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsVCELIMTX
Revenue $306.30M $48.61M
Gross profit $228.38M –
Operating income $18.24M -$264.59M
Net income $24.22M -$240.97M
Free cash flow $61.66M -$244.28M
R&D $29.17M $254.77M
EPS (diluted) $0.46 $-1.97
Cash & equivalents $125.40M $265.52M
Shares (diluted) 52.31M 122.35M
Enterprise value $1.64B -$1.13B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricVCELIMTX
P/E 90.8x -3.6x
P/FCF 35.7x -3.9x
P/Operating cash flow 31.6x -4.0x
P/S 7.2x 19.7x
P/B 6.0x 2.1x
P/Tangible book 6.0x 2.1x
EV/EBITDA 65.0x -2.0x
EV/EBIT 111.9x -1.9x
EV/Revenue 6.7x 10.5x
EV/FCF 33.1x -2.1x
EV/Operating cash flow 29.3x -2.1x
PEG (3Y EPS CAGR) 1.67 0.15

Growth

14 metrics
MetricVCELIMTX
Revenue growth (1Y) 23.0% -65.4%
Revenue CAGR (3Y) 19.8% -47.1%
Gross profit growth (1Y) 24.8% –
Gross profit CAGR (3Y) 23.9% –
Operating income growth (1Y) 1,428% -176.1%
Operating income CAGR (3Y) 47.8% -58.8%
Net income growth (1Y) 240.8% -187.4%
Net income CAGR (3Y) 56.6% -37.5%
EPS growth (1Y) 228.1% -180.7%
EPS CAGR (3Y) 54.3% -23.8%
Operating cash flow growth (1Y) 47.5% -33.6%
Operating cash flow CAGR (3Y) 33.7% -39.1%
Free cash flow growth (1Y) 842.9% -29.2%
Free cash flow CAGR (3Y) 43.2% -30.7%

Profitability

14 metrics
MetricVCELIMTX
Gross margin 74.6% –
EBITDA margin 10.2% -515.5%
Operating margin 6.0% -544.3%
Pretax margin 8.2% -496.3%
Net margin 7.9% -495.7%
FCF margin 20.1% -502.6%
Operating cash flow margin 22.7% -493.8%
Return on equity 6.9% -49.2%
Return on assets 5.1% -40.9%
Return on invested capital – –
Return on capital employed 4.1% -50.5%
Asset turnover 0.6x 0.1x
Cash conversion (OCF / net income) 2.9x 1.0x
Stock comp / revenue 12.2% 42.1%

Financial Health

11 metrics
MetricVCELIMTX
Debt / assets – –
Debt / equity – –
Net debt / EBITDA – –
Debt / FCF – –
Liabilities / assets 26.4% 17.7%
Equity / assets 73.6% 82.3%
Interest coverage 28.5x -3.2x
Current ratio 5.0x 7.5x
Quick ratio 4.5x 7.0x
Cash ratio 3.1x 6.9x
Altman Z-score 10.12 2.67

Shareholder Returns

7 metrics
MetricVCELIMTX
Dividend yield – –
Net buyback yield -0.3% -15.8%
Shareholder yield -0.3% -15.8%
Payout ratio (earnings) – –
Payout ratio (FCF) – –
Dividend growth (1Y) – –
Dividend CAGR (3Y) – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusVCELIMTX
Forward P/E 84.4xFY2026 –
EPS, next fiscal year $0.51FY2026 $-2.10FY2026
EPS growth, next FY +59.4%FY2026 –
EPS growth, the year after +74.5% –
Revenue, next fiscal year $324.56MFY2026 $40.64MFY2026
Revenue growth, next FY +17.5%FY2026 -28.4%FY2026
Revenue growth, the year after +16.1% -11.9%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersVCELIMTX
Held by institutions 100.0% 81.6%
Institutions holding 317 83
Change in shares held, QoQ +0.4% -7.8%
Institutions buying 187 37
Institutions selling 98 33
Buyers to sellers 1.91 1.12

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

VCELIMTX
VCEL 1.00 0.12
IMTX 0.12 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, VCEL and IMTX?

Vericel (VCEL) is the largest by market capitalisation: Vericel (VCEL) $2.22B, Immatics (IMTX) $899.26M.

Which company is growing faster?

Vericel (VCEL) grew revenue fastest over the trailing twelve months: Vericel (VCEL) +23.0%, Immatics (IMTX) -65.4%.

Which company is more profitable?

Vericel (VCEL) has the highest net margin (Vericel (VCEL) 7.9%, Immatics (IMTX) -495.7%).

Which stock has performed better?

Over the past year Vericel (VCEL) returned the most: Vericel (VCEL) +18.5%, Immatics (IMTX) -29.8%. Over five years, Vericel (VCEL) compounded fastest (Vericel (VCEL) -3.2%/yr, Immatics (IMTX) -11.9%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Vericel (VCEL) has been the steadiest (Vericel (VCEL) 40.9%, Immatics (IMTX) 57.7%). Volatility measures how widely the price swings, not the risk of the business.

Do VCEL and IMTX move together?

Their daily returns over the past year have a correlation of 0.12, a weak relationship. Holding both diversifies more than two closely linked stocks would.

Which is the better stock, VCEL and IMTX?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Vericel (VCEL) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.